HER2-TARGETING CHIMERIC ANTIGEN RECEPTOR MYELOID CELLS DERIVED FROM EXPANDED CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR OVARIAN CANCER IMMUNOTHERAPY
$301,279FY2022Department of the ArmyDOD
Immunebridge Inc.
Investigators
View source on USAspending →HER2-TARGETING CHIMERIC ANTIGEN RECEPTOR MYELOID CELLS DERIVED FROM EXPANDED CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR OVARIAN CANCER IMMUNOTHERAPY · GrantIndex